Roquefort Therapeutics (LSE:ROQ) Ending Cash Position : £0.54 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Roquefort Therapeutics Ending Cash Position?

Roquefort Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2023 was £0.54 Mil.

Roquefort Therapeutics's quarterly Ending Cash Position declined from Dec. 2022 (£2.32 Mil) to Jun. 2023 (£1.38 Mil) and declined from Jun. 2023 (£1.38 Mil) to Dec. 2023 (£0.54 Mil).

Roquefort Therapeutics's annual Ending Cash Position increased from Dec. 2021 (£0.00 Mil) to Dec. 2022 (£2.32 Mil) but then declined from Dec. 2022 (£2.32 Mil) to Dec. 2023 (£0.54 Mil).

Roquefort Therapeutics Ending Cash Position Historical Data

The historical data trend for Roquefort Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roquefort Therapeutics Ending Cash Position Chart

Roquefort Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Ending Cash Position

2.32

0.54

Roquefort Therapeutics Semi-Annual Data
	Jun21	Jun22	Dec22	Jun23	Dec23
Ending Cash Position	0.88	3.33	2.32	1.38	0.54

Roquefort Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Roquefort Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	2.323	+	-1.786
	=	0.54

Roquefort Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	1.379	+	-0.842
	=	0.54

Roquefort Therapeutics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Roquefort Therapeutics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Roquefort Therapeutics (LSE:ROQ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roquefort Therapeutics PLC (LSE:ROQ) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

ROQAF:USA

Address

85 Great Portland Street, First Floor, London, GBR, W1W 7LT

Website

https://www.roquefortplc.com

Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses that are at an early stage in the medical sector including Drug and vaccine development; Diagnostics; Immuno-therapy; and Cell and gene therapies. The principal activity of the Company is to develop pre-clinical next generation medicines focused on hard to treat cancers.

Roquefort Therapeutics (LSE:ROQ) Headlines

No Headlines